Biology subjects

Rajao, M. A.

Publications and source records attributed to Rajao, M. A..

3 recordsLinked to original sources

bioRxiv2026

Identification, expression and subcellular localization of Leishmania amazonensis and Leishmania infantum Phospholipases A1

Leishmaniases remain a significant global public health threat, with Leishmania amazonensis and Leishmania infantum representing the etiological agents of the cutaneous and visceral forms in the Americas, respectively. Building on our previous identification of Phospholipase A1 (PLA1) in Leishmania braziliensis, this study provides a comprehensive molecular, immunological, and biochemical characterization of PLA1 in L. amazonensis and L. infantum promastigotes. We analyzed PLA1 activity and expression, purified the recombinant enzyme from L. amazonensis, and validated protein expression using a specific anti-PLA1 serum. The major contribution of this research is the first description of the subcellular localization of a PLA1 within the Leishmania genus. Moreover, our results reveal an unprecedented association between PLA1 and lipid droplets within the parasites. This discovery is of particular interest as it provides the first evidence linking this enzyme to lipid storage organelles in Leishmania. Given that PLA1 is an established virulence factor in other trypanosomatids, these findings suggest a specialized role for the enzyme in parasite lipid metabolism and potentially in its pathogenic mechanisms, opening new perspectives for understanding Leishmania biology.

microbiology↗

bioRxiv2025

SEPSIS-INDUCED LIPID DROPLET ACCUMULATION ENHANCES ANTIBACTERIAL INNATE IMMUNITY

Lipid droplets (LDs) are lipid-rich organelles recognized as central players in lipid homeostasis, signaling, and inflammation. While their functions in inflammation are well-documented, the role of LDs in antibacterial immunity and infection resistance remains less understood. In this study, we investigated triglyceride synthesis and LD accumulation in the context of antibacterial innate immunity during sepsis. Our results show that LD accumulation is part of immunometabolic reprogramming in E. coli-infected macrophages. Pharmacological inhibition or genetic knockdown of DGAT1, a key enzyme in triglyceride synthesis, reduced LD formation, bacterial clearance, and pro-inflammatory responses (nitric oxide, PGE2, CCL2, IL-6, IFN-{beta}). Notably, DGAT1 inhibition impaired the expression of several interferon-stimulated genes (ISGs), including viperin, iNOS, cathelicidin, and IGTP, in E. coli-infected macrophages. In a sepsis model, DGAT1 inhibition reduced sepsis-induced LD accumulation in peritoneal cells and decreased levels of CCL2, IFN-{beta}, nitric oxide, and lipid mediators (PGE2, LTB4, and RvD1). Furthermore, DGAT1 inhibition accelerated sepsis-related mortality, coinciding with elevated bacterial loads in the peritoneum and bloodstream at 6 and 24 hours post-sepsis. Our results demonstrate that tryglicerides synthesis and LDs are critical regulators of infection resistance, contributing to both bacterial clearance and the coordination of a protective proinflammatory response during sepsis.

immunology↗

bioRxiv2025

Resistance to BRAF inhibitors drives melanoma sensitivity to Chk1 inhibition

BRAF inhibitor-resistant melanomas (BRAFiR) acquire (epi)genetic and functional alterations that enable them to evade alternative treatments. Identifying these alterations is critical to advancing treatment strategies. Here, we explored the effect of Chk1 inhibition (Chk1i) on BRAFiR cells, revealing higher sensitivity compared to treatment-naive cells both in vitro and in vivo. Using FUCCI-labeling and time-lapse microscopy, we show that S phase progression is required for Chk1i-induced cytotoxicity in BRAFiR cells, but not in treatment-naive cells. Replication stress markers, including reduced BrdU incorporation and increased phospho-RPA and {gamma}H2AX, were exclusive to BRAFiR cells exposed to Chk1i. Untreated BRAFiR cells exhibited upregulated DNA replication genes, reduced progressing forks and increased origin firing, suggesting intrinsic replication changes. MAPK pathway reactivation in treatment-naive cells mimicked BRAFiR traits, increasing sensitivity to Chk1i. These findings indicate that Chk1i exploits elevated replication stress specifically in BRAFiR, highlighting its therapeutic potential in overcoming MAPK inhibitor resistance in melanoma.

cancer biology↗